Kura Oncology Depreciation & Amortization Growth & History (KURA)
Kura Oncology's depreciation and amortization was $1.0M for fiscal 2025.
View full Kura Oncology company overviewKura Oncology annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $1.0M | $184,000 | +21.70% |
| 2024 | 2024-12-31 | $848,000 | −$1,000 | −0.12% |
| 2023 | 2023-12-31 | $849,000 | $90,000 | +11.86% |
| 2022 | 2022-12-31 | $759,000 | $201,000 | +36.02% |
| 2021 | 2021-12-31 | $558,000 | $364,000 | +187.63% |
| 2020 | 2020-12-31 | $194,000 | $194,000 | — |
| 2019 | 2019-12-31 | $0 | −$10,000 | — |
| 2018 | 2018-12-31 | $10,000 | −$20,000 | −66.67% |
| 2017 | 2017-12-31 | $30,000 | −$1,000 | −3.23% |
| 2016 | 2016-12-31 | $31,000 | $11,000 | +55.00% |
| 2015 | 2015-12-31 | $20,000 | — | — |
Kura Oncology quarterly depreciation and amortization
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $369,000 | $145,000 | +64.73% |
| Q1 2026 | 2026-03-31 | $355,000 | $114,000 | +47.30% |
| Q4 2025 | 2025-12-31 | $403,000 | — | — |
| Q3 2025 | 2025-09-30 | $164,000 | −$44,000 | −21.15% |
| Q2 2025 | 2025-06-30 | $224,000 | $22,000 | +10.89% |
| Q1 2025 | 2025-03-31 | $241,000 | $7,000 | +2.99% |
| Q3 2024 | 2024-09-30 | $208,000 | −$8,000 | −3.70% |
| Q2 2024 | 2024-06-30 | $202,000 | −$11,000 | −5.16% |
| Q1 2024 | 2024-03-31 | $234,000 | $28,000 | +13.59% |
| Q3 2023 | 2023-09-30 | $216,000 | $23,000 | +11.92% |
| Q2 2023 | 2023-06-30 | $213,000 | $30,000 | +16.39% |
| Q1 2023 | 2023-03-31 | $206,000 | $29,000 | +16.38% |
| Q3 2022 | 2022-09-30 | $193,000 | $33,000 | +20.63% |
| Q2 2022 | 2022-06-30 | $183,000 | $59,000 | +47.58% |
| Q1 2022 | 2022-03-31 | $177,000 | $69,000 | +63.89% |
| Q3 2021 | 2021-09-30 | $160,000 | $86,000 | +116.22% |
| Q2 2021 | 2021-06-30 | $124,000 | — | — |
| Q1 2021 | 2021-03-31 | $108,000 | — | — |
| Q3 2020 | 2020-09-30 | $74,000 | — | — |
| Q3 2018 | 2018-09-30 | $1,000 | −$6,000 | −85.71% |
| Q2 2018 | 2018-06-30 | $4,000 | −$4,000 | −50.00% |
| Q1 2018 | 2018-03-31 | $5,000 | −$3,000 | −37.50% |
| Q3 2017 | 2017-09-30 | $7,000 | −$1,000 | −12.50% |
| Q2 2017 | 2017-06-30 | $8,000 | $1,000 | +14.29% |
| Q1 2017 | 2017-03-31 | $8,000 | $0 | 0.00% |
| Q3 2016 | 2016-09-30 | $8,000 | $1,000 | +14.29% |
| Q2 2016 | 2016-06-30 | $7,000 | $4,000 | +133.33% |
| Q1 2016 | 2016-03-31 | $8,000 | $5,000 | +166.67% |
| Q3 2015 | 2015-09-30 | $7,000 | — | — |
| Q2 2015 | 2015-06-30 | $3,000 | — | — |
| Q1 2015 | 2015-03-31 | $3,000 | — | — |
Kura Oncology depreciation and amortization trends
Over the last five fiscal years, Kura Oncology's depreciation and amortization increased from $194,000 to $1.0M, a change of $838,000. The latest reported quarter, Q2 2026, shows $369,000.
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Kura Oncology source filings ↗